Vera Therapeutics (NASDAQ:VERA) Sees Strong Trading Volume – Should You Buy?

Vera Therapeutics, Inc. (NASDAQ:VERA) saw unusually-high trading volume on Thursday . Approximately 972,614 shares changed hands during trading, a decline of 21% from the previous session’s volume of 1,223,724 shares.The stock last traded at $39.3340 and had previously closed at $42.66.

Analyst Ratings Changes

A number of equities analysts have issued reports on VERA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research note on Wednesday, March 11th. Finally, TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Vera Therapeutics Trading Down 12.9%

The company has a 50 day simple moving average of $36.11 and a 200 day simple moving average of $41.41. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The company has a market capitalization of $2.67 billion, a PE ratio of -6.73 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the business earned ($0.81) earnings per share. Analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $37.93, for a total value of $701,705.00. Following the completion of the transaction, the chief executive officer directly owned 198,244 shares of the company’s stock, valued at approximately $7,519,394.92. This represents a 8.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 59,951 shares of company stock worth $2,392,387 in the last three months. 15.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VERA. Janus Henderson Group PLC grew its holdings in shares of Vera Therapeutics by 26.7% during the first quarter. Janus Henderson Group PLC now owns 17,658 shares of the company’s stock worth $710,000 after buying an additional 3,723 shares in the last quarter. ADAR1 Capital Management LLC raised its position in shares of Vera Therapeutics by 8.8% in the first quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock valued at $645,000 after buying an additional 1,300 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Vera Therapeutics by 31.5% in the first quarter. California State Teachers Retirement System now owns 49,737 shares of the company’s stock worth $2,001,000 after buying an additional 11,907 shares in the last quarter. Royal Bank of Canada lifted its stake in shares of Vera Therapeutics by 190.6% in the first quarter. Royal Bank of Canada now owns 19,987 shares of the company’s stock worth $804,000 after buying an additional 13,108 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its stake in shares of Vera Therapeutics by 72.6% in the first quarter. Quantinno Capital Management LP now owns 25,639 shares of the company’s stock worth $1,031,000 after buying an additional 10,784 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.